Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will present preclinical data from its SNP3-targeting Huntington’s disease (HD) program at the CHDI Foundation’s 15th Annual Huntington’s Disease Therapeutics Conference, being held February 24-27, 2020, in Palm Springs, California. The poster presentation will include preclinical in vivo and in vitro data for Wave’s investigational allele-selective stereopure oligonucleotides designed to preferentially target the mutant huntingtin (mHTT) mRNA transcript associated with a single nucleotide polymorphism (SNP3).

Wave’s HD pipeline includes its Phase 1b/2a investigational oligonucleotides targeting SNP1 (WVE-120101) and SNP2 (WVE-120102), as well as its SNP3-targeting oligonucleotides. All of these oligonucleotides are designed to be allele-selective and preferentially lower mHTT protein while keeping the level of healthy or wild-type HTT (wtHTT) protein relatively intact. The wtHTT protein is important for neuronal function, and there is increasing evidence that it may be neuroprotective in an adult brain. Additionally, a dominant gain of function in mHTT protein and a concurrent loss of function of wtHTT protein may be important components of the pathophysiology of HD.

Details of Data Presentation

  • Poster: Stereopure oligonucleotides for the selective silencing of mutant huntingtin
    Wednesday, February 26, 2020
    1:00-4:00 p.m. PST

About Wave Life Sciences’ Clinical Research in Huntington’s Disease
Wave is developing WVE-120101 and WVE-120102, which are investigational stereopure antisense oligonucleotides designed to selectively target the mutant huntingtin (mHTT) mRNA transcript of SNP rs362307 (SNP1) and SNP rs362331 (SNP2), respectively. SNPs are naturally occurring variations within a given genetic sequence and in certain instances can be used to distinguish between two related copies of a genetic transcript where only one is associated with the CAG expansion that leads to expression of mHTT protein.

WVE-120101 and WVE-120102 are currently being investigated in early manifest HD patients in the Phase 1b/2a PRECISION-HD1 and PRECISION-HD2 studies, respectively. In December 2019, Wave announced initial data from PRECISION-HD2 showing mHTT target engagement and that WVE-120102 was generally safe and well tolerated across all cohorts. Based on these data, Wave announced the addition of a higher dose cohort to each study with the intention to explore higher doses. Results from PRECISION-HD1 and PRECISION-HD2, including from the next cohort in each study (32mg), are expected in the second half of 2020.

In addition to WVE-120101 and WVE-120102, Wave expects to initiate clinical development of a SNP3-targeting candidate in the second half of 2020. Between its SNP1, SNP2 and SNP3 programs, Wave has the potential to address up to 80% of the HD patient population. Wave’s allele-selective approach may also enable the company to address the pre-manifest, or asymptomatic, HD patient population in the future.


Source: Wawe Life Science

Related article

57 Condivisioni